Executive Vice President, European Commercial · TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Richard Daniell

A named executive officer of TEVA PHARMACEUTICAL INDUSTRIES in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,433,292

Salary $836,753Stock awards $3,299,990

FY2023: $5,164,163

4th of 5 named executive officers at Teva Pharmaceutical Industries by FY2024 total.

5 named officers on file for TEVA PHARMACEUTICAL INDUSTRIES, FY2024

Richard Daniell’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • TEVA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TEVA PHARMACEUTICAL INDUSTRIES’s whole pay program stands against its peers

  • TEVA PHARMACEUTICAL INDUSTRIES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TEVA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 9, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Richard Daniell’s full pay file as a PDF — free

More than this page: up to 10 years of Richard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Richard Daniell compensation by year

TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · all 2 fiscal years held
In US dollars, as TEVA PHARMACEUTICAL INDUSTRIES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$772,754$836,753
Bonus$0$0
Stock awards$3,499,986$3,299,990
Option awards$0$0
Non-equity incentive$743,372$1,134,888
Pension and deferred compensation$0$0
All other$148,051$161,661
Total$5,164,163$5,433,292

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed April 9, 2025, accession 0001193125-25-076829, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TEVA PHARMACEUTICAL INDUSTRIES LTD filed document, accession 0001193125-25-076829. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2025.

$5.2M
$5.4M
FY23
FY24
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU186,753$4,116,036—
PSU183,169$4,037,045—
PSU110,668$2,439,123—
RSU81,845$1,803,864—
RSU67,024$1,477,209—
PSU40,923$901,943—
RSU22,576$497,575—

Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

30 Form 4 lines since the FY2024 proxy (filed April 9, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-11Exercise or conversion—20,003$34.7075,758
2026-11-11Exercise or conversion derivative—20,003$0.000
2026-11-11Sale—20,003$42.8055,755
2026-11-09Exercise or conversion derivative—25,000$0.0020,003
2026-11-09Sale—25,000$42.9155,755
2026-11-09Exercise or conversion—25,000$34.7080,755
2026-05-05Sale—30,000$35.4055,755
2026-03-05Exercise or conversion derivative10b5-117,295$0.0051,887

The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Richard FrancisPresident and Chief Executive Officer$15,518,947
Eli KalifExecutive Vice President, Chief Financial Officer$6,175,059
Eric HughesExecutive Vice President, Global R&D and Chief Medical Officer$5,754,787
Richard Daniell · this pageExecutive Vice President, European Commercial$5,433,292
Christine FoxExecutive Vice President, US Commercial$5,218,023

The full TEVA PHARMACEUTICAL INDUSTRIES compensation record

free company brief

This page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TEVA PHARMACEUTICAL INDUSTRIES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Richard Daniell's compensation dossier · One-time report. No refunds.